(+)-JQ1

Name: (+)-JQ1
Brand: Selleck Chemicals
SKU: S7110
Rating: 5 (271 reviews)

For research use only.

Catalog No.S7110

271 publications

CAS No. 1268524-70-4

(+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family. (+)-JQ1 suppresses cell proliferation via inducing autophagy. (+)-JQ1 inhibits the expression of Nuclear receptor binding SET domain protein 3 (NSD3) target genes.

Selleck's (+)-JQ1 has been cited by 271 publications

Cell, 2021, S0092-8674(21)00354-8

PubMed: 33811809 ( click the link to review the publication )

Cell, 2020, 182(4):992-1008.e21

PubMed: 32710817 ( click the link to review the publication )

Nat Genet, 2020, 52(4):408-417

PubMed: 32203462 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cancer Cell, 2018, 34(2):271-285.e7

PubMed: 30107177 ( click the link to review the publication )

Cancer Cell, 2018, 33(3):512-526

PubMed: 29533787 ( click the link to review the publication )

Cancer Cell, 2018, 33(3):401-416

PubMed: 29533782 ( click the link to review the publication )

Nat Med, 2017, 23(4):493-500

PubMed: 28263307 ( click the link to review the publication )

Nat Med, 2017, 23(9):1046-1054

PubMed: 28805821 ( click the link to review the publication )

Cancer Discov, 2017, 7(3):302-321

PubMed: 28108460 ( click the link to review the publication )

Cancer Cell, 2017, 31(5):635-652

PubMed: 28434841 ( click the link to review the publication )

Gastroenterology, 2014, 147(5):1119-33

PubMed: 25127677 ( click the link to review the publication )

Cell Rep, 2021, 34(7):108750

PubMed: 33596424 ( click the link to review the publication )

J Exp Clin Cancer Res, 2021, 40(1):106

PubMed: 33741018 ( click the link to review the publication )

Cancers (Basel), 2021, 13(6)1376

PubMed: 33803654 ( click the link to review the publication )

PLoS Pathog, 2021, 17(1):e1009091

PubMed: 33411730 ( click the link to review the publication )

Mol Cancer Ther, 2021, 20(4):691-703

PubMed: 33509905 ( click the link to review the publication )

J Virol, 2021, JVI.02124-20

PubMed: 33762408 ( click the link to review the publication )

Am J Cancer Res, 2021, 11(2):530-545

PubMed: 33575085 ( click the link to review the publication )

EBioMedicine, 2021, 65:103241

PubMed: 33647768 ( click the link to review the publication )

Cell Rep, 2021, 34(7):108749

PubMed: 33596420 ( click the link to review the publication )

Adv Sci (Weinh), 2020, 16;7(7):1902926

PubMed: 32274304 ( click the link to review the publication )

Nat Commun, 2020, 29;11(1):2086

PubMed: 32350249 ( click the link to review the publication )

Nat Commun, 2020, 11(1):71

PubMed: 31900415 ( click the link to review the publication )
Proc Natl Acad Sci U S A, 2020, 202021450

PubMed: 33310900 ( click the link to review the publication )

Clin Cancer Res, 2020, clincanres.2246.2020

PubMed: 33109736 ( click the link to review the publication )

Cancer Res, 2020, canres.1030.2020

PubMed: 32934021 ( click the link to review the publication )

J Hematol Oncol, 2020, 13(1):80

PubMed: 32552902 ( click the link to review the publication )

J Exp Clin Cancer Res, 2020, 39(1):261

PubMed: 33239043 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2668

PubMed: 32962010 ( click the link to review the publication )

Cell Death Dis, 2020, 17;11(4):239

PubMed: 32303673 ( click the link to review the publication )

Br J Cancer, 2020, 4

PubMed: 32362655 ( click the link to review the publication )

Mol Ther Nucleic Acids, 2020, 6;19:109-123

PubMed: 31837602 ( click the link to review the publication )

J Mol Cell Biol, 2020, 11;12(5):359-371

PubMed: 31565729 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(5):4547-4557

PubMed: 32163373 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(1):397-415

PubMed: 31901895 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(10):9240-9259

PubMed: 32392533 ( click the link to review the publication )

Carcinogenesis, 2020, 41(9):1282-1293

PubMed: 31826234 ( click the link to review the publication )

Epigenetics, 2020, 22:1-13

PubMed: 32164487 ( click the link to review the publication )

Cell Oncol (Dordr), 2020, 10.1007/s13402-020-00497-6

PubMed: 32166583 ( click the link to review the publication )

Cancer Sci, 2020, 111(10):3503-3515

PubMed: 32726482 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(2):523-535

PubMed: 32195024 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(1):148-163

PubMed: 32064158 ( click the link to review the publication )

Oncogenesis, 2020, 9(3):33

PubMed: 32157097 ( click the link to review the publication )

ACS Chem Biol, 2020, 17;15(4):895-903

PubMed: 32176478 ( click the link to review the publication )

J Immunol, 2020, 204(5):1242-1254

PubMed: 31988180 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Front Oncol, 2020, 10:565820

PubMed: 33134168 ( click the link to review the publication )
J Cell Mol Med, 2020, 10.1111/jcmm.15901

PubMed: 32954665 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(2):1650-1657

PubMed: 31821686 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(18)E6873

PubMed: 32961679 ( click the link to review the publication )

Sci Rep, 2020, 10(1):15837

PubMed: 32985581 ( click the link to review the publication )

Sci Rep, 2020, 10(1):19723

PubMed: 33184327 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-00570-8

PubMed: 33311600 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-00504-4

PubMed: 32855528 ( click the link to review the publication )

Int J Biol Macromol, 2020, 164:3204-3220

PubMed: 32860796 ( click the link to review the publication )

Front Pharmacol, 2020, 8;11:618

PubMed: 32457617 ( click the link to review the publication )

Int J Oncol, 2020, 56(6):1429-1441

PubMed: 32236593 ( click the link to review the publication )

Exp Cell Res, 2020, 24:112034

PubMed: 32339606 ( click the link to review the publication )

Med Sci Monit, 2020, 8;26:e923411

PubMed: 32266878 ( click the link to review the publication )

Br J Cancer, 2020, 122(6):789-800

PubMed: 31932756 ( click the link to review the publication )

Cancer Discov, 2020, CD-20-0160

PubMed: 32703768 ( click the link to review the publication )

Cancer Cell, 2020, 37(4):584-598

PubMed: 32220301 ( click the link to review the publication )

Front Oncol, 2020, 9:1471

PubMed: 31993368 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01393-x

PubMed: 32747750 ( click the link to review the publication )

Mol Oncol, 2020, 10.1002

PubMed: 32175692 ( click the link to review the publication )

Int J Cancer, 2020, 10.1002/ijc.33222

PubMed: 32683685 ( click the link to review the publication )

Cancer Lett, 2020, 491:50-59

PubMed: 32735909 ( click the link to review the publication )

Inflamm Regen, 2020, 40:25

PubMed: 33072227 ( click the link to review the publication )

Blood Adv, 2020, 4(20):5062-5077

PubMed: 33080008 ( click the link to review the publication )

Cell Death Dis, 2020, 11(8):673

PubMed: 32826850 ( click the link to review the publication )

Sci Transl Med, 2019, 11(497)

PubMed: 31217338 ( click the link to review the publication )
Blood, 2019, 134(21):1821-1831

PubMed: 31527074 ( click the link to review the publication )

Nat Commun, 2019, 10(1):335

PubMed: 30659195 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3201

PubMed: 31324758 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(2)

PubMed: 30610113 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(10):e9930

PubMed: 31476112 ( click the link to review the publication )

Genome Res, 2019, 29(10):1659-1672

PubMed: 31515287 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 116(6):2220-2225

PubMed: 30659143 ( click the link to review the publication )

Cancer Res, 2019, 79(9):2415-2425

PubMed: 30885979 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):277

PubMed: 31653272 ( click the link to review the publication )

Theranostics, 2019, 9(13):3840-3852

PubMed: 31281517 ( click the link to review the publication )

Cancer Res, 2019, 79(19):4869-4881

PubMed: 31311807 ( click the link to review the publication )

Cancer Res, 2019, 79(18):4599-4611

PubMed: 31358529 ( click the link to review the publication )

Cell Rep, 2019, 28(13):3497-3509

PubMed: 31553917 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Elife, 2019, 8

PubMed: 30652970 ( click the link to review the publication )

J Hematol Oncol, 2019, 12(1):73

PubMed: 31288832 ( click the link to review the publication )

Redox Biol, 2019, 24:101195

PubMed: 31004990 ( click the link to review the publication )

Oncogene, 2019, 38(47):7249-7265

PubMed: 31420604 ( click the link to review the publication )

Cancer Lett, 2019, 442:373-382

PubMed: 30419347 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):383

PubMed: 31470872 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):83

PubMed: 30770740 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):463

PubMed: 31718704 ( click the link to review the publication )

Cell Death Dis, 2019, 10(8):557

PubMed: 31324754 ( click the link to review the publication )
Cell Death Dis, 2019, 10(4):324

PubMed: 30975979 ( click the link to review the publication )

Cell Death Dis, 2019, 10(11):815

PubMed: 31653826 ( click the link to review the publication )

Addict Biol, 2019, 10.1111/adb.12808

PubMed: 31364211 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(11):2111-2123

PubMed: 31467179 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Epigenetics, 2019, 10.1080/15592294.2019.1656156

PubMed: 31423932 ( click the link to review the publication )

J Thorac Cardiovasc Surg, 2019, 10.1016/j.jtcvs.2019.06.115

PubMed: 31564537 ( click the link to review the publication )

Sci Rep, 2019, 9(1):13305

PubMed: 31527644 ( click the link to review the publication )

Sci Rep, 2019, 9(1):17369

PubMed: 31758083 ( click the link to review the publication )

Biomed Pharmacother, 2019, 114:108793

PubMed: 30921702 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2019, 60(14):4748-4758

PubMed: 31731295 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):1251

PubMed: 31881855 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 519(3):481-488

PubMed: 31530390 ( click the link to review the publication )

J Oral Pathol Med, 2019, 10.1111/jop.12906

PubMed: 31177574 ( click the link to review the publication )

SLAS Discov, 2019, 24(2):142-157

PubMed: 30204533 ( click the link to review the publication )

Mol Med Rep, 2019, 19(1):499-507

PubMed: 30483785 ( click the link to review the publication )

Oncol Lett, 2019, 18(3):2340-2347

PubMed: 31452730 ( click the link to review the publication )

Can J Physiol Pharmacol, 2019, 97(11):1028-1034

PubMed: 31330113 ( click the link to review the publication )

Nucleic Acids Res, 2019, gkz1139

PubMed: 31822909 ( click the link to review the publication )

Leukemia, 2019, 10.1038/s41375-019-0682-7

PubMed: 31862959 ( click the link to review the publication )

Phytomedicine, 2019, 67:153163

PubMed: 31901891 ( click the link to review the publication )

Journal of Oral Pathology & Medicine, 2019, 10.1111/jop.12906

PubMed: 无 ( click the link to review the publication )

Mol Cell, 2018, 72(2):341-354

PubMed: 30270106 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):387-401

PubMed: 29200404 ( click the link to review the publication )
Nat Commun, 2018, 9(1):1532

PubMed: 29670088 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3815

PubMed: 30232459 ( click the link to review the publication )

EMBO J, 2018, 37(5)

PubMed: 29440228 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(40):E9317-E9324

PubMed: 30181285 ( click the link to review the publication )

J Am Soc Nephrol, 2018, 29(6):1690-1705

PubMed: 29739813 ( click the link to review the publication )

Cancer Res, 2018, 78(10):2705-2720

PubMed: 29490948 ( click the link to review the publication )

Cancer Res, 2018, 78(20):5731-5740

PubMed: 30135193 ( click the link to review the publication )

Cell Rep, 2018, 22(8):2016-2025

PubMed: 29466730 ( click the link to review the publication )

Cell Rep, 2018, 24(7):1722-1729

PubMed: 30110629 ( click the link to review the publication )

Oncogene, 2018, 37(28):3763-3777

PubMed: 29636547 ( click the link to review the publication )

J Med Chem, 2018, 61(2):453-461

PubMed: 28378579 ( click the link to review the publication )

Cancers (Basel), 2018, 10(1)

PubMed: 29346274 ( click the link to review the publication )

Clin Epigenetics, 2018, 10:01

PubMed: 29312470 ( click the link to review the publication )

Cell Death Dis, 2018,

PubMed: 29988031 ( click the link to review the publication )

Cells, 2018, 7(10)

PubMed: 30304769 ( click the link to review the publication )

Exp Mol Med, 2018, 50(1):e419

PubMed: 29303513 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 50(2):798-809

PubMed: 30308485 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2796-2810

PubMed: 30242092 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(7):1554-1565

PubMed: 29716963 ( click the link to review the publication )

Gynecol Oncol, 2018, 149(3):575-584

PubMed: 29567272 ( click the link to review the publication )

J Virol, 2018, 92(10)

PubMed: 29343578 ( click the link to review the publication )

J Virol, 2018, 92(2)

PubMed: 29118124 ( click the link to review the publication )

Epigenetics Chromatin, 2018, 11(1):30

PubMed: 29884215 ( click the link to review the publication )

Sci Rep, 2018, 8(1):3521

PubMed: 29476067 ( click the link to review the publication )
Sci Rep, 2018, 8(1):998

PubMed: 29343723 ( click the link to review the publication )

Sci Rep, 2018, 8(1):18043

PubMed: 30575780 ( click the link to review the publication )

Front Microbiol, 2018, 9:2022

PubMed: 30283406 ( click the link to review the publication )

J Biol Chem, 2018, 293(16):5808-5820

PubMed: 29475942 ( click the link to review the publication )

Int J Oncol, 2018, 53(6):2503-2517

PubMed: 30272279 ( click the link to review the publication )

Retrovirology, 2018, 15(1):36

PubMed: 29751762 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2018, 59(1):132-143

PubMed: 29332125 ( click the link to review the publication )

Bioorg Med Chem, 2018, 26(1):25-36

PubMed: 29170024 ( click the link to review the publication )

Int J Stem Cells, 2018, 11(1):131-140

PubMed: 29699387 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 499(3):531-537

PubMed: 29596834 ( click the link to review the publication )

Leuk Lymphoma, 2018, 59(4):931-940

PubMed: 28750570 ( click the link to review the publication )

Leuk Lymphoma, 2018, 59(5):1248-1251

PubMed: 28885069 ( click the link to review the publication )

Oncotarget, 2018, 9(41):26491-26506

PubMed: 29899872 ( click the link to review the publication )

Oncotarget, 2018, 9(71):33482-33499

PubMed: 30323893 ( click the link to review the publication )

Blood Adv, 2018, 2(23):3428-3442

PubMed: 30504235 ( click the link to review the publication )

Oncotarget, 2018, 9(11):9907-9924

PubMed: 29515779 ( click the link to review the publication )

Oncotarget, 2018, 9(41):26491-26506

PubMed: 29899872 ( click the link to review the publication )

Oncotarget, 2018, 9(83):35408-35421

PubMed: 30459933 ( click the link to review the publication )

JCI Insight, 2018, 3(19)

PubMed: 30282829 ( click the link to review the publication )

JCI Insight, 2018, 3(16)

PubMed: 30135308 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(5):569-579

PubMed: 28494238 ( click the link to review the publication )

Nat Chem Biol, 2017, 13(6):681-690

PubMed: 28437395 ( click the link to review the publication )

Nat Commun, 2017, 8:16078

PubMed: 28714472 ( click the link to review the publication )

Nat Commun, 2017, 8:14802

PubMed: 28378740 ( click the link to review the publication )
Nat Commun, 2017, 8(1):1067

PubMed: 29057925 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(14):8403-8410

PubMed: 28854735 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(15):4462-4472

PubMed: 28270499 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(36):E7554-E7563

PubMed: 28784769 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(27):E5352-E5361

PubMed: 28630312 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(43):E9135-E9144

PubMed: 29073110 ( click the link to review the publication )

Genes Dev, 2017, 31(12):1212-1227

PubMed: 28724615 ( click the link to review the publication )

Cancer Res, 2017, 77(20):5564-5575

PubMed: 28819026 ( click the link to review the publication )

J Am Soc Nephrol, 2017, 28(2):504-519

PubMed: 27436852 ( click the link to review the publication )

Mol Syst Biol, 2017, 13(1):905

PubMed: 28069687 ( click the link to review the publication )

Cell Rep, 2017, 21(10):2796-2812

PubMed: 29212027 ( click the link to review the publication )

Haematologica, 2017, 102(10):1776-1784

PubMed: 28751557 ( click the link to review the publication )

Cell Mol Immunol, 2017, 14(4):371-379

PubMed: 26388239 ( click the link to review the publication )

Sci Signal, 2017, 10(508)

PubMed: 29208683 ( click the link to review the publication )

J Med Chem, 2017, 60(24):9990-10012

PubMed: 29172540 ( click the link to review the publication )

J Med Chem, 2017, 60(14):6289-6304

PubMed: 28650658 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1436-1449

PubMed: 28923910 ( click the link to review the publication )

Cancer Discov, 2017, 7(8):852-867

PubMed: 28408401 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(2):285-299

PubMed: 27980108 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1739-1750

PubMed: 28572168 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(6):1054-1067

PubMed: 28336808 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(6):1155-1165

PubMed: 28246302 ( click the link to review the publication )

Biochim Biophys Acta Mol Basis Dis, 2017, 1863(12):3001-3015

PubMed: 28844955 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(1):35-44

PubMed: 27707886 ( click the link to review the publication )
Mol Cancer Res, 2017, 15(8):984-997

PubMed: 28442587 ( click the link to review the publication )

Sci Rep, 2017, 7(1):8027

PubMed: 28808321 ( click the link to review the publication )

Skelet Muscle, 2017, 7(1):16

PubMed: 28870238 ( click the link to review the publication )

J Chem Inf Model, 2017, 57(7):1677-1690

PubMed: 28636361 ( click the link to review the publication )

Org Biomol Chem, 2017, 15(44):9352-9361

PubMed: 29087414 ( click the link to review the publication )

Biomed Pharmacother, 2017, 95:1574-1579

PubMed: 28950657 ( click the link to review the publication )

J Agric Food Chem, 2017, 65(22):4384-4394

PubMed: 28471170 ( click the link to review the publication )

Cell Biosci, 2017, 7:56

PubMed: 29118968 ( click the link to review the publication )

Molecules, 2017, 23(1)

PubMed: 29295560 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:2581-2593

PubMed: 28553123 ( click the link to review the publication )

J Gen Virol, 2017, 98(4):799-809

PubMed: 28113052 ( click the link to review the publication )

Biol Res, 2017, 50(1):19

PubMed: 28545522 ( click the link to review the publication )

Oncotarget, 2017, 8(18):29558-29573

PubMed: 28418907 ( click the link to review the publication )

Oncotarget, 2017, 8(23):37140-37153

PubMed: 28415755 ( click the link to review the publication )

Oncotarget, 2017, 9(9):8334-8349

PubMed: 29492199 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107206-107222

PubMed: 29291023 ( click the link to review the publication )

Oncotarget, 2017, 8(58):98068-98083

PubMed: 29228674 ( click the link to review the publication )

Oncotarget, 2017, 8(49):86312-86324

PubMed: 29156797 ( click the link to review the publication )

Oncotarget, 2017, 8(31):51402-51415

PubMed: 28881656 ( click the link to review the publication )

Oncotarget, 2017, 8(58):98471-98481

PubMed: 29228703 ( click the link to review the publication )

J Chem Inf Model, 2017, 57(7):1677-1690

PubMed: 28636361 ( click the link to review the publication )

Oncotarget, 2017, 8(12):19478-19490

PubMed: 28061448 ( click the link to review the publication )

Sci Rep, 2017, 7(1):16646

PubMed: 29192216 ( click the link to review the publication )

Nat Chem Biol, 2016, 12(7):504-10

PubMed: 27159579 ( click the link to review the publication )
EMBO Mol Med, 2016, 8(2):117-38

PubMed: 26681773 ( click the link to review the publication )

Clin Cancer Res, 2016, 10.1158/1078-0432.CCR-15-2448

PubMed: 27401245 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(42):11865-11870

PubMed: 27679845 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(31):E4558-66

PubMed: 27432991 ( click the link to review the publication )

Cancer Res, 2016, 76(11):3319-31

PubMed: 26988986 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(17):4440-51

PubMed: 27103402 ( click the link to review the publication )

Cancer Res, 2016, 76(5):1204-13

PubMed: 26837760 ( click the link to review the publication )

Cancer Res, 2016, 76(8):2376-83

PubMed: 26941288 ( click the link to review the publication )

Cancer Res, 2016, 76(6):1313-9

PubMed: 26759243 ( click the link to review the publication )

Cell Rep, 2016, 16(5):1366-1378

PubMed: 27425608 ( click the link to review the publication )

Cell Rep, 2016, 15(2):310-22

PubMed: 27050521 ( click the link to review the publication )

J Hematol Oncol, 2016, 9(1):134

PubMed: 27903272 ( click the link to review the publication )

PLoS Pathog, 2016, 12(10):e1005950

PubMed: 27764245 ( click the link to review the publication )

Clin Epigenetics, 2016, 8:76

PubMed: 27437033 ( click the link to review the publication )

PLoS Genet, 2016, 12(9):e1006279

PubMed: 27588951 ( click the link to review the publication )

Cancer Discov, 2016, 6(6):612-29

PubMed: 27099234 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0750

PubMed: 26939702 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(6):1217-26

PubMed: 26983878 ( click the link to review the publication )

J Virol, 2016, 90(18):8059-73

PubMed: 27356901 ( click the link to review the publication )

J Biol Chem, 2016, 291(41):21694-21702

PubMed: 27576686 ( click the link to review the publication )

Oncol Rep, 2016, 36(4):1989-96

PubMed: 27573714 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 469(3):679-85

PubMed: 26707881 ( click the link to review the publication )

Oncotarget, 2016, 6(7):5134-46

PubMed: 25762617 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6576-92

PubMed: 26536665 ( click the link to review the publication )
Sci Rep, 2016, 6:23770

PubMed: 27044328 ( click the link to review the publication )

Oncotarget, 2016, 8(32):52193-52210

PubMed: 28881723 ( click the link to review the publication )

Oncotarget, 2016, 7(48):79637-79653

PubMed: 27793034 ( click the link to review the publication )

Blood, 2015, 126(13):1565-74

PubMed: 26254443 ( click the link to review the publication )

Nat Commun, 2015, 6:10091

PubMed: 26631872 ( click the link to review the publication )

Sci Adv, 2015, 1(8):e1500221

PubMed: 26601252 ( click the link to review the publication )

Cancer Res, 2015, 75(21):4548-59

PubMed: 26483207 ( click the link to review the publication )

J Hematol Oncol, 2015, 8:121

PubMed: 26515759 ( click the link to review the publication )

EBioMedicine, 2015, 3:108-121

PubMed: 26870822 ( click the link to review the publication )

Arch Toxicol, 2015, 89(2):179-91

PubMed: 25559776 ( click the link to review the publication )

Epigenetics, 2015, 10.1080/15592294.2015.1034416

PubMed: 25941994 ( click the link to review the publication )

Sci Rep, 2015, 5:16445

PubMed: 26563568 ( click the link to review the publication )

Sci Rep, 2015, 5:10120

PubMed: 25944566 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(4):580-8

PubMed: 25793663 ( click the link to review the publication )

Exp Ther Med, 2015, 10(6):2319-2324

PubMed: 26668635 ( click the link to review the publication )

Oncotarget, 2015, 6(22):18921-32

PubMed: 26254279 ( click the link to review the publication )

Oncotarget, 2015, 6(11):8722-35

PubMed: 25749378 ( click the link to review the publication )

Oncotarget, 2015, 6(32):33623-35

PubMed: 26378038 ( click the link to review the publication )

Oncotarget, 2015, 6(25):21507-21

PubMed: 26087189 ( click the link to review the publication )

Nat Chem Biol, 2014, 10(4):305-12

PubMed: 24584101 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2014, 111(26):E2721-30

PubMed: 24979794 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2014, 111(26):9503-8

PubMed: 24979803 ( click the link to review the publication )

Cancer Res, 2014, 74(23):7090-102

PubMed: 25277525 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(11):2898-909

PubMed: 24714777 ( click the link to review the publication )
Cancer Res, 2014, 74(21):5999-6009

PubMed: 25164011 ( click the link to review the publication )

Mol Cell Proteomics, 2014, 13(11):2896-910

PubMed: 25106422 ( click the link to review the publication )

Epigenetics, 2014, 9(4):611-20

PubMed: 24496381 ( click the link to review the publication )

Drug Metab Dispos, 2013, 41(10):1725-31

PubMed: 23918665 ( click the link to review the publication )

PLoS One, 2013, 8(5):e63563

PubMed: 23704919 ( click the link to review the publication )

Nat Chem Biol, 2012, 8(11):905-912

PubMed: 23023260 ( click the link to review the publication )

Handb Exp Pharmacol, 2011, 206:1-12

PubMed: 21879443 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Target Protein Ligand Inhibitors

Biological Activity

Description

Features

(+)-JQ1 is more effective than (-)-JQ1.

Targets

BRD4 (2) ^[1] (Cell-free assay)	BRD4 (1) ^[1] (Cell-free assay)
33 nM	77 nM

In vitro

(+)-JQ1 enantiomer binds directly into the Kac binding site of BET bromodomains. (+)-JQ1 (500 nM) binds BRD4 competitively with chromatin resulting in differentiation and growth arrest of NMC cells. (+)-JQ1 (500 nM) attenuates rapid proliferation of NMC 797 and Per403 cell lines as demonstrated by reduced Ki67 staining. (+)-JQ1 (500 nM) potently decreases expression of both BRD4 target genes in NMC 797 cells. (+)-JQ1 inhibits cellular viability with IC50 of 4 nM in NMC 11060 cells. ^[1] (+)-JQ1 results in robust inhibition of MYC expression in MM cell lines. (+)-JQ1 inhibits proliferating of KMS-34 and LR5 with IC50 of 68 nM and 98 nM, respectively. (+)-JQ1 (500 nM)-treated MM.1S cells results in a pronounced decrease in the proportion of cells in S-phase, with a concomitant increase in cells arrested in G0/G1. (+)-JQ1 (500 nM) results in pronounced cellular senescence by beta-galactosidase staining. (+)-JQ1 (800 nM) exposure leads to a significant reduction in cell viability among the majority of CD138+ patient-derived MM samples tested. ^[2] (+)-JQ1 inhibits growth of LP-1 cells with GI50 of 98 nM. (+)-JQ1 (625 nM) results in an increase in the percentage of LP-1 cells in G0/G1. (+)-JQ1 (500 nM) suppresses the expression of MYC, BRD4 and CDK9 in LP-1 cells. ^[3] (+)-JQ1 (1 μM) activates HIV transcription in latently infected Jurkat T cells. (+)-JQ1 (50 μM) stimulates predominantly Tat-dependent HIV transcription in both Jurkat and HeLa cells. (+)-JQ1 (5 μM) induces Brd4 dissociation enables Tat to recruit SEC to HIV promoter and induce Pol II CTD phosphorylation and viral transcription in J-Lat A2 cells. JQ1 enables Tat to increase CDK9 T-loop phosphorylation and partially dissociates P-TEFb from 7SK snRNP in Jurkat T cells. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
K1	Mmr0R4VtdCCYaXHibYxqfHliQYPzZZk>	M1T2[VI2OC93MECvNVAxOCCwTR?=	NX76NmQ3OjRxNEivO\|IhcA>?	M1zBPGROW09?	M1zZW4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI>	M33XSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{C3PFgyLz5{NkewO\|g5OTxxYU6=
BCPAP	MkLaR4VtdCCYaXHibYxqfHliQYPzZZk>	NXnlWG5ZOjVyL{WwNE8yODByIH7N	MojSNlQwPDhxN{KgbC=>	NGHlUZJFVVOR	NFXRcYhqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz	M13yeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{C3PFgyLz5{NkewO\|g5OTxxYU6=
K1	MWnD[YxtKEO7Y3zlJGF{e2G7	NF\GS2czPTBxNUCwM\|ExODBibl2=	MYe3NkBp	M1nYXmROW09?	NFj0TGhienKnc4TzJINmdGxiY4njcIUh[XRiR{CvS\|EheGijc3W=	M37WRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{C3PFgyLz5{NkewO\|g5OTxxYU6=
BCPAP	M2nFVWNmdGxiQ4njcIUhSXO\|YYm=	NIK3Z4EzPTBxNUCwM\|ExODBibl2=	MX:3NkBp	MYrEUXNQ	NFO2XFBienKnc4TzJINmdGxiY4njcIUh[XRiR{CvS\|EheGijc3W=	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjdyN{i4NUc,OjZ5MEe4PFE9N2F-
Hep3B	NWnsbIdqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\G[FkxNTFyIN88US=>	MYC1JIQ>	MVTEUXNQ	MX;JR\|UxRTBwMEig{txO	MoXkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3N{WxOlcoRjJ4NUe1NVY4RC:jPh?=
HCCLM3	NFXCNXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1zzWFAuOTBizszN	MkP4OUBl	MXTEUXNQ	M1vIbWlEPTB;MD6xOEDPxE1?	NFm1XI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW3OVE3Pyd-Mk[1O\|UyPjd:L3G+
HuH7	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\xXnZFOC1zMDFOwG0>	M3vqb\|Uh\A>?	MlnlSG1UVw>?	MlnQTWM2OD1yLkKxJO69VQ>?	NVH0b\|hERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1O\|UyPjdpPkK2OVc2OTZ5PD;hQi=>
HepG2	NFeyZmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rGUlAuOTBizszN	Ml7zOUBl	M2W0[WROW09?	MlzlTWM2OD1yLkO0JO69VQ>?	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV5NUG2O{c,OjZ3N{WxOlc9N2F-
SMMC7721	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml7wNE0yOCEQvF2=	MXW1JIQ>	M1jZUWROW09?	MlHwTWM2OD1yLkSxJO69VQ>?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV5NUG2O{c,OjZ3N{WxOlc9N2F-
BEL7402	M3\iPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{\rVVAuOTBizszN	NHXSTFE2KGR?	Ml7iSG1UVw>?	MUnJR\|UxRTBwNEeg{txO	NHTZNHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW3OVE3Pyd-Mk[1O\|UyPjd:L3G+
MHCC97H	NGTQb2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnXCNE0yOCEQvF2=	M1S1WVUh\A>?	M3zVRmROW09?	MmHOTWM2OD1yLkSxJO69VQ>?	MlfWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3N{WxOlcoRjJ4NUe1NVY4RC:jPh?=
Hep3B	NF\rWIxE\WyuIFP5Z4xmKEG\|c3H5	MorXNE4yNzBwNT:yMlUh\|ryP	MXG0PEBp	MnTnSG1UVw>?	NWrpVHlkdGWjZIOgeI8h[SC\|dXLzeIFvfGmjbDDhZ4N2dXWuYYTpc44hd2ZiSFPDJINmdGy\|IHnuJJN2[i2JMTDwbIF{\cLi	M{DYc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NUe1NVY4Lz5{NkW3OVE3PzxxYU6=
HCCLM3	Ml\jR4VtdCCFeXPs[UBCe3OjeR?=	MkftNE4yNzBwNT:yMlUh\|ryP	NX;FPZREPDhiaB?=	MYTEUXNQ	MV\s[YFleyC2bzDhJJN2[nO2YX70bYFtKGGlY4XteYxifGmxbjDv[kBJS0NiY3XscJMhcW5ic4XiMWcyKHCqYYPlxsA>	M4DBXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NUe1NVY4Lz5{NkW3OVE3PzxxYU6=
Hep3B	NIqxXmhCeG:ydH;zbZMhSXO\|YYm=	M4K1[VAvOS9yLkWvNk42KM7:TR?=	NWjjNZdNPDhiaB?=	MmLNSG1UVw>?	MorhZYN1cX[jdHXzJINie3Cjc3WtN{BidmRiY3HzdIF{\S17IHX4dJJme3Orb36gZY5lKGmwZIXj[YQhWEGUUDDjcIVifmGpZTDhd{B4\WyuIHHzJIN6fG:laILvcYUh[yC{ZXzlZZNmKGmwdH:geIhmKGO7dH;wcIF{dSCocn;tJI1qfG:laH;u[JJq[Q>?	M2fXPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NUe1NVY4Lz5{NkW3OVE3PzxxYU6=
HCCLM3	NYC0dJVzSXCxcITvd4l{KEG\|c3H5	M4[xWVAvOS9yLkWvNk42KM7:TR?=	MkHYOFghcA>?	MVfEUXNQ	NVXwNm5E[WO2aY\heIV{KGOjc4Dhd4UuOyCjbnSgZ4F{eGG\|ZT25JIV5eHKnc4Ppc44h[W6mIHnu[JVk\WRiUFHSVEBkdGWjdnHn[UBieyC5ZXzsJIF{KGO7dH;jbJJwdWViYzDy[Yxm[XOnIHnueI8hfGinIHP5eI9xdGG\|bTDmdo9uKG2rdH;jbI9v\HKrYR?=	NETLV4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW3OVE3Pyd-Mk[1O\|UyPjd:L3G+
A549	NED0b2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUiwMlEuOTBizszN	M4OxcFczKGh?		MmfhbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NX\vZppURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0NVUzOjVpPkK2OFE2OjJ3PD;hQi=>
H157	NH2xZmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYiwMlEuOTBizszN	NIG2XI84OiCq		MWHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NXrE[JE1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0NVUzOjVpPkK2OFE2OjJ3PD;hQi=>
H1299	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGDpVnYxNjFvMUCg{txO	NF;VbFI4OiCq		NF7Fe3ZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NXv6U5NrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0NVUzOjVpPkK2OFE2OjJ3PD;hQi=>
A549	NI\aO\|hHfW6ldHnvckBCe3OjeR?=	MofBNU8zNjVxNTFOwG0>	MYSxNkBp		MoLaxsB4\WGtbImg[IVkemWjc3XkJGJkdC1{IHzleoVtew>?	M3TOZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NEG1NlI2Lz5{NkSxOVIzPTxxYU6=
H1299	MW\GeY5kfGmxbjDBd5NigQ>?	NGfob\|kyNzJwNT:1JO69VQ>?	MlfINVIhcA>?		MXpCpJdm[WuueTDk[YNz\WG\|ZXSgRoNtNTJibHX2[Yx{	M{Xxe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NEG1NlI2Lz5{NkSxOVIzPTxxYU6=
H157	NXfBdGVETnWwY4Tpc44hSXO\|YYm=	NGG5flIyNzJwNT:1JO69VQ>?	MmDUNVIhcA>?		Mnjv[IVkemWjc3XkJGRTPCCneIDy[ZN{cW:w	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjRzNUKyOUc,OjZ2MUWyNlU9N2F-
H1299	MU\GeY5kfGmxbjDBd5NigQ>?	MWKxM\|IvPS93IN88US=>	NV\iOpI{OTJiaB?=		Mniy[IVkemWjc3XkJGRTPCCneIDy[ZN{cW:w	MmfHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ2MUWyNlUoRjJ4NEG1NlI2RC:jPh?=
C8161	NVzoSZdNS2WubDDWbYFjcWyrdImgRZN{[Xl?	MoKzNE0zKM7:TR?=	Mn\kOEBl	Mlr3SG1UVw>?	NIW1XG9l\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	Mn:yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|OUeyNlMoRjJ4M{m3NlI{RC:jPh?=
Mel285	Ml3ZR4VtdCCYaXHibYxqfHliQYPzZZk>	M1ruT\|AuOiEQvF2=	MWe0JIQ>	M2\nXmROW09?	MUHk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NXvLXlBxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zPVczOjNpPkK2N\|k4OjJ\|PD;hQi=>
Mel290	NX25UWk2S2WubDDWbYFjcWyrdImgRZN{[Xl?	MmLPNE0zKM7:TR?=	M2\0fVQh\A>?	NUXkfZBoTE2VTx?=	Ml7y[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NFX2fIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO5O\|IzOyd-Mk[zPVczOjN:L3G+
92.1	NEfIZ5VE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NUPBVJE1OC1{IN88US=>	MkHFOEBl	NFT2R\|BFVVOR	NHTQV2Jl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NHjWXYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO5O\|IzOyd-Mk[zPVczOjN:L3G+
Omm1.3	MYLD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MXOwMVIh\|ryP	M4XRUVQh\A>?	M1\TVWROW09?	MVzk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NXv6SZk4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zPVczOjNpPkK2N\|k4OjJ\|PD;hQi=>
Mel202	MYXD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NV;WOYlGOC1{IN88US=>	MkHwOEBl	NV7GfHNmTE2VTx?=	Mnq4[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MnOyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|OUeyNlMoRjJ4M{m3NlI{RC:jPh?=
Mel270	Mk[yR4VtdCCYaXHibYxqfHliQYPzZZk>	MoLzNE0zKM7:TR?=	MWK0JIQ>	NWPuSndxTE2VTx?=	Mkjl[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NHLacGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO5O\|IzOyd-Mk[zPVczOjN:L3G+
Omm1	MUDD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NGjDT4kxNTJizszN	M1TkNlQh\A>?	M4LVd2ROW09?	NV71UHpS\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	M2fOTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{m3NlI{Lz5{NkO5O\|IzOzxxYU6=
92.1	NUn0T2RnSXCxcITvd4l{KEG\|c3H5	NGW4WZA2ODBibl2=	MVq0PEBp	NFPqW3BFVVOR	NF;PNIpqdmS3Y3XzJIFxd3C2b4Ppdy=>	MnjpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|OUeyNlMoRjJ4M{m3NlI{RC:jPh?=
Omm1.3	NX6wXGZzSXCxcITvd4l{KEG\|c3H5	MXS1NFAhdk1?	NYrweZF4PDhiaB?=	MkXySG1UVw>?	NHvwZ29qdmS3Y3XzJIFxd3C2b4Ppdy=>	Moq2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|OUeyNlMoRjJ4M{m3NlI{RC:jPh?=
92.1	MXzD[YxtKEO7Y3zlJGF{e2G7	NXj2XIhCPTByIH7N	MmL5NlQwPDhxN{KgbC=>	NEnWc\|NFVVOR	M322dYlv\HWlZYOgeIhmKGOnbHygZYNkfW23bHH0bY9vKGG2IIP1Zk1IOcLi	NV6wUndsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zPVczOjNpPkK2N\|k4OjJ\|PD;hQi=>
Omm1.3	NGfPdGVE\WyuIFP5Z4xmKEG\|c3H5	NFfXRpU2ODBibl2=	MWmyOE81QC95MjDo	MlTvSG1UVw>?	MU\pcoR2[2W\|IITo[UBk\WyuIHHjZ5VufWyjdHnvckBifCC\|dXKtS\|HDqA>?	NEHifYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO5O\|IzOyd-Mk[zPVczOjN:L3G+
A549	M4HvUmZ2dmO2aX;uJGF{e2G7	MWCxNFAwPDByL{GwNFAhdk1?	NYHRNmw4OjRiaB?=		MmrTeZBz\We3bHH0[ZMh[W6mIHHjeIl3[XSnczDTTXJVOQ>?	M{jabVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkGyNVk6Lz5{NkKxNlE6QTxxYU6=
MCF-7	MmLjSpVv[3Srb36gRZN{[Xl?	NETNeowyODBxNECwM\|ExODBibl2=	MkGyNlQhcA>?		MUH1dJJm\3WuYYTld{BidmRiYXP0bZZifGW\|IGPJVnQy	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJzMkG5PUc,OjZ{MUKxPVk9N2F-
HEK293	NInYblVHfW6ldHnvckBCe3OjeR?=	MWSxNFAwPDByL{GwNFAhdk1?	NHT6Z4szPCCq		M1f4R5VxemWpdXzheIV{KGGwZDDhZ5RqfmG2ZYOgV2lTXDF?	MlXCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{MUKxPVkoRjJ4MkGyNVk6RC:jPh?=
858	NVzZcFl4S2WubDDWbYFjcWyrdImgRZN{[Xl?	NESxbmkxNTFizszN	NVLnNFB[PSCm	MnuwSG1UVw>?	NULxVWpM\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MmT0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{ME[zN\|MoRjJ4MkC2N\|M{RC:jPh?=
DDR2L63V	M1\H[GNmdGxiVnnhZoltcXS7IFHzd4F6	NVnNOZdiOC1zIN88US=>	NYP1OpBIPSCm	NITxOG1FVVOR	NILlbJdl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NXPpRopCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yNFY{OzNpPkK2NlA3OzN\|PD;hQi=>
BE(2)-C	NVzWXJpkS2WubDDWbYFjcWyrdImgRZN{[Xl?	NH:ySJYyKM7:TR?=	M{TqcFEuPCCm		NV7lTIc3\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl?	NWXwVldVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOlc1PjRpPkK2NFY4PDZ2PD;hQi=>
IMR-32	M2rDfWNmdGxiVnnhZoltcXS7IFHzd4F6	NFHjNW0yKM7:TR?=	M2joNFEuPCCm		M3LQcIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6	NUTubFF2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOlc1PjRpPkK2NFY4PDZ2PD;hQi=>
JF	MV3D[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M2jObFEh\|ryP	M3rkZlEuPCCm		NGPzZ3Fl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>?	NFv5clI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC2O\|Q3PCd-Mk[wOlc1PjR:L3G+
BE(2)-M17	MnO0R4VtdCCYaXHibYxqfHliQYPzZZk>	NGjzZ5gyKM7:TR?=	M2S0dFEuPCCm		NVz3eFh2\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl?	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB4N{S2OEc,OjZyNke0OlQ9N2F-
SK-N-SH	MVHD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NVnCUnZkOSEQvF2=	M3\PO\|EuPCCm		NFrZUZVl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>?	NEDwVHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC2O\|Q3PCd-Mk[wOlc1PjR:L3G+
SK-N-DZ	NFjmXIhE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NFjqNVQyKM7:TR?=	Ml;hNU01KGR?		MYPk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHlic3nncolncWOjboTsfS=>	MoPrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNke0OlQoRjJ4ME[3OFY1RC:jPh?=
HMC-1.1	M1f3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnzQOU02ODByIH7N	Ml7wOFghcA>?	NWq5VnZHTE2VTx?=	MUXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB3NUOwN{c,OjZyNUWzNFM9N2F-
HMC-1.2	NWDn[HRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFX3ZWM2NTVyMECgcm0>	MWC0PEBp	NVTqNW96TE2VTx?=	MnfxbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	M3nlbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEW1N\|A{Lz5{NkC1OVMxOzxxYU6=
ROSA KIT WT	MlTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV[1MVUxODBibl2=	MlTGOFghcA>?	NUP6N3JXTE2VTx?=	NHXrOmJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB3NUOwN{c,OjZyNUWzNFM9N2F-
ROSA KIT D816V	Mo\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M13i[lUuPTByMDDuUS=>	MXi0PEBp	NF3ne3ZFVVOR	NH74XY1qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	M1fMNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEW1N\|A{Lz5{NkC1OVMxOzxxYU6=
HMC-1.1	NIjDOYtCeG:ydH;zbZMhSXO\|YYm=	MYWyNFAuPTByMDDuUS=>	M1jQUlQ5KGh?	MlzzSG1UVw>?	NIfKOHNqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NIXjXmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC1OVMxOyd-Mk[wOVU{ODN:L3G+
HMC-1.2	NVL2cGxRSXCxcITvd4l{KEG\|c3H5	MY[yNFAuPTByMDDuUS=>	MXG0PEBp	NXTEXmVVTE2VTx?=	NU\lOmoxcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	Mk\NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNUWzNFMoRjJ4MEW1N\|A{RC:jPh?=
ROSA KIT WT	NVP4TmlYSXCxcITvd4l{KEG\|c3H5	M{fCNFIxOC13MECwJI5O	NEPNUHg1QCCq	NVHOPWVDTE2VTx?=	Ml3sbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MlHMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNUWzNFMoRjJ4MEW1N\|A{RC:jPh?=
ROSA KIT D816V	MmLjRZBweHSxc3nzJGF{e2G7	MmXYNlAxNTVyMECgcm0>	NWjnWmpLPDhiaB?=	MXnEUXNQ	MlXObY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NXXGZ4VlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOVU{ODNpPkK2NFU2OzB\|PD;hQi=>
494H	NYqySY9[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3nVNlczKGh?	MYjEUXNQ	NIjwZldKSzVyPUCuNVIzyrFyLkCwOEDPxE1?	NXXoS45VRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OFQ2PjZpPkK1PVQ1PTZ4PD;hQi=>
493H	Mo\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2\S[\|czKGh?	NUHmU\|FMTE2VTx?=	M4TySGlEPTB;MD6wOFfDuTBwMEC5JO69VQ>?	NWDHcpgyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OFQ2PjZpPkK1PVQ1PTZ4PD;hQi=>
716H	NGDsSW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXu3NkBp	NIW4NnFFVVOR	NGLk[HZKSzVyPUCuNlEzyrFyLkCzOEDPxE1?	Mo\mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NES1OlYoRjJ3OUS0OVY3RC:jPh?=
148I	MkmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M33xd\|czKGh?	M1v3UmROW09?	MkH6TWM2OD1yLkK4OOKyOC5yM{Wg{txO	MkfkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NES1OlYoRjJ3OUS0OVY3RC:jPh?=
98Sc	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUL1W4JZPzJiaB?=	Mkm4SG1UVw>?	MYXJR\|UxRTBwMUG1xtExNjByNDFOwG0>	NUfjVYlERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OFQ2PjZpPkK1PVQ1PTZ4PD;hQi=>
89R	NHjobWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYDjR4pGPzJiaB?=	MVnEUXNQ	MWXJR\|UxRTBwMUK2xtExNjByMzFOwG0>	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl2NEW2Okc,OjV7NES1OlY9N2F-
494L	M4LsRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnmxO\|IhcA>?	MUPEUXNQ	NVTIUnNIUUN3ME2wMlMyP8LzMD6wNVIh\|ryP	M1;k[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUS0OVY3Lz5{NUm0OFU3PjxxYU6=
493L	Mk\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MV:3NkBp	MofYSG1UVw>?	MmXOTWM2OD1yLkC1NOKyOC5yMUGg{txO	Mkm3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NES1OlYoRjJ3OUS0OVY3RC:jPh?=
148L	MnvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHXmVHg4OiCq	NX31ZlF1TE2VTx?=	M{La[GlEPTB;MD6xOFbDuTBwMEG3JO69VQ>?	M3nCelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUS0OVY3Lz5{NUm0OFU3PjxxYU6=
98L	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4XlW\|czKGh?	NH64RXlFVVOR	NEH1NpJKSzVyPUCuN\|A6yrFyLkCyPUDPxE1?	M3LYblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUS0OVY3Lz5{NUm0OFU3PjxxYU6=
OS17	NWXNRpl7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MW[3NkBp	MYjEUXNQ	M{XZO2lEPTB;MD6wO\|nDuTBwMECzJO69VQ>?	M1zFVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUS0OVY3Lz5{NUm0OFU3PjxxYU6=
OS9	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MV:3NkBp	M2DKSmROW09?	M3;vemlEPTB;MD60NFbDuTBwMEK4JO69VQ>?	NE\xZYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm0OFU3Pid-MkW5OFQ2PjZ:L3G+
MG63	NEDKbYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVm3NkBp	M3fKRWROW09?	MoC5TWM2OD1yLkGxOOKyOC5yMkWg{txO	NUDkU5oyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OFQ2PjZpPkK1PVQ1PTZ4PD;hQi=>
SAOS2	NFOwUWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1H0U\|czKGh?	NID5UXJFVVOR	MYPJR\|UxRTBwMkG3xtExNjByMzFOwG0>	NEL1cGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm0OFU3Pid-MkW5OFQ2PjZ:L3G+
U2OS	MlzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWm3NkBp	NHjqVY1FVVOR	NUH2bIExUUN3ME2wMlE6QMLzMD6wNFgh\|ryP	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl2NEW2Okc,OjV7NES1OlY9N2F-
SJSA-1	NGS4OohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVS3NkBp	NH3uelZFVVOR	MUPJR\|UxRTBwMUCwxtExNjBzMDFOwG0>	NWTwcGxnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OFQ2PjZpPkK1PVQ1PTZ4PD;hQi=>
494H	MVTBdI9xfG:\|aYOgRZN{[Xl?	M3W5UVAvOjVxMD61M\|EvOCEQvF2=	MXWyOEBp	NVrGUWdVTE2VTx?=	MlrQbY5kemWjc3XzJIxmfmWuczDv[kBkdGWjdnXkJINie3Cjc3WtN:Kh	M3rtWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUS0OVY3Lz5{NUm0OFU3PjxxYU6=
148I	NXixWJp{SXCxcITvd4l{KEG\|c3H5	M4XENlAvOjVxMD61M\|EvOCEQvF2=	NX[xfVd[OjRiaB?=	MnLvSG1UVw>?	MlmzbY5kemWjc3XzJIxmfmWuczDv[kBkdGWjdnXkJINie3Cjc3WtN:Kh	NIX5W2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm0OFU3Pid-MkW5OFQ2PjZ:L3G+
OS17	M1LQZWFxd3C2b4Ppd{BCe3OjeR?=	M3[5XVAvOjVxMD61M\|EvOCEQvF2=	NG\CbIkzPCCq	NHK0ZnlFVVOR	MXzpcoNz\WG\|ZYOgcIV3\Wy\|IH;mJINt\WG4ZXSgZ4F{eGG\|ZT2zxsA>	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl2NEW2Okc,OjV7NES1OlY9N2F-
494H	MoDxRZBweHSxc3nzJGF{e2G7	MVex5qCK\|ryP	NGizTG01QCCq	NELhZllFVVOR	MXrpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KHOrZ37p[olk[W62bIm=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl2NEW2Okc,OjV7NES1OlY9N2F-
148I	M2S0VmFxd3C2b4Ppd{BCe3OjeR?=	MUix5qCK\|ryP	NX3keY9JPDhiaB?=	M{\XSGROW09?	Ml\wbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC\|aXfubYZq[2GwdHz5	M2HMdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUS0OVY3Lz5{NUm0OFU3PjxxYU6=
OS17	NITDd2VCeG:ydH;zbZMhSXO\|YYm=	MmTJNgKBkc7:TR?=	MWC0PEBp	MVjEUXNQ	NETHUHpqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IIPp[45q\mmlYX70cJk>	NEDWXWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm0OFU3Pid-MkW5OFQ2PjZ:L3G+
MOLM13	NV3lSFhOSXCxcITvd4l{KEG\|c3H5	MoHyNlUxKG6P	NYjiR3RSPDhiaB?=	M2n3UWROW09?	NVXNfXF4cW6mdXPld{B{cWewaX\pZ4FvfGy7IHHwc5B1d3OrczDjc5Rz\WG2bXXueEB4cXSqIIH1bZpienSrbnni	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB3M{iyOUc,OjVyNUO4NlU9N2F-
MV4-11	MULBdI9xfG:\|aYOgRZN{[Xl?	NIriflUzPTBibl2=	MVi0PEBp	NIHmO3RFVVOR	NHLod2tqdmS3Y3XzJJNq\26rZnnjZY51dHliYYDvdJRwe2m\|IHPveJJm[XSvZX70JJdqfGhicYXpfoFzfGmwaXK=	MoLKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNUO4NlUoRjJ3MEWzPFI2RC:jPh?=
MOLM13	MYrGeY5kfGmxbjDBd5NigQ>?	NVTu[IgxOjVyIH7N	NEfN[I8zPCCq	M2fuNmROW09?	MVzlcohidmOnczDxeYl7[XK2aX7pZk1qdmS3Y3XkJI1wemVicEKxMEBDUU1uIHHu[EBkdGWjdnXkJHBCWlB?	MnS2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNUO4NlUoRjJ3MEWzPFI2RC:jPh?=
MV4-11	MoP1SpVv[3Srb36gRZN{[Xl?	MVuyOVAhdk1?	NWnwPIh2OjRiaB?=	NWrvOoVUTE2VTx?=	NFXXXGdmdmijbnPld{ByfWm8YYL0bY5q[i2rbnT1Z4VlKG2xcnWgdFIyNCCESV2sJIFv\CClbHXheoVlKFCDUmC=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB3M{iyOUc,OjVyNUO4NlU9N2F-
MOLM13	M1PzZ2Fxd3C2b4Ppd{BCe3OjeR?=	M2\hZlI2OCCwTR?=	M3r6S\|Q5KGh?	M13DSWROW09?	NXfYN2JycW6mdXPld{B{cWewaX\pZ4FvfGy7IHHwc5B1d3OrczDjc5Rz\WG2bXXueEB4cXSqIIDvcoF1cW6rYh?=	NYD4eGw2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOVM5OjVpPkK1NFU{QDJ3PD;hQi=>
MV4-11	NGXKbYdCeG:ydH;zbZMhSXO\|YYm=	NG\FfVAzPTBibl2=	NWLDT4pxPDhiaB?=	Ml;5SG1UVw>?	Mo\mbY5lfWOnczDzbYdvcW[rY3HueIx6KGGyb4D0c5NqeyClb4Ty[YF1dWWwdDD3bZRpKHCxbnH0bY5q[g>?	NWLsSHV3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOVM5OjVpPkK1NFU{QDJ3PD;hQi=>
Hela	NULUZ5d3S2WubDDWbYFjcWyrdImgRZN{[Xl?	NVGwNZdROC13MECgcm0>	NEPXe404OiCq	NF;KNmFFVVOR	NEjMUG9l\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	M4mw[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEC5Nlk2Lz5{NUCwPVI6PTxxYU6=
HBL-1	MnjIR4VtdCCYaXHibYxqfHliQYPzZZk>	Mnu4NE02ODBibl2=	NGnUWIE4OiCq	MmTnSG1UVw>?	NYTOboEx\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	M1v1UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEC5Nlk2Lz5{NUCwPVI6PTxxYU6=
HLY-1	MVTD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NV\HW2VKOC13MECgcm0>	NV7iO2VuPzJiaB?=	MofhSG1UVw>?	NGn4b\|hl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTByOUK5OUc,OjVyMEmyPVU9N2F-
OCI-Ly3	NWiwfpZ1S2WubDDWbYFjcWyrdImgRZN{[Xl?	NF\MVWMxNTVyMDDuUS=>	NX7OVFlrPzJiaB?=	MmOxSG1UVw>?	NHXhfIxl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NVLyOWQ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNFkzQTVpPkK1NFA6Ojl3PD;hQi=>
OCI-Ly10	M3jNdmNmdGxiVnnhZoltcXS7IFHzd4F6	M{\PdFAuPTByIH7N	NEDoeWw4OiCq	MVjEUXNQ	NGr6[nRl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NUPJ[VB5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNFkzQTVpPkK1NFA6Ojl3PD;hQi=>
SU-DHL-4	MXnD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M2ribVAuPTByIH7N	MXK3NkBp	M1q0NmROW09?	NHLlZW5l\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	M13BfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEC5Nlk2Lz5{NUCwPVI6PTxxYU6=
SU-DHL-5	Ml3tR4VtdCCYaXHibYxqfHliQYPzZZk>	NX3DVZplOC13MECgcm0>	MkfiO\|IhcA>?	MmDySG1UVw>?	MonM[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NFvVblA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCwPVI6PSd-MkWwNFkzQTV:L3G+
SU-DHL-6	Ml3ER4VtdCCYaXHibYxqfHliQYPzZZk>	NYTTVJlDOC13MECgcm0>	NUXUVZZQPzJiaB?=	NXS2W5F5TE2VTx?=	M3qyNIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NFrOXnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCwPVI6PSd-MkWwNFkzQTV:L3G+
SU-DHL-10	NEXwW25E\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MVWwMVUxOCCwTR?=	NWP5OGJ6PzJiaB?=	NYXZPXR3TE2VTx?=	NFmxSYVl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTByOUK5OUc,OjVyMEmyPVU9N2F-
RC-K8	M{nnT2NmdGxiVnnhZoltcXS7IFHzd4F6	MlKxNE02ODBibl2=	MWG3NkBp	MnfYSG1UVw>?	MWjk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NYnrcIxyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNFkzQTVpPkK1NFA6Ojl3PD;hQi=>
OCI-Ly8	MVvD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NHfFU20xNTVyMDDuUS=>	NFnBcVU4OiCq	MVXEUXNQ	MoDS[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NWHZPYZvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNFkzQTVpPkK1NFA6Ojl3PD;hQi=>
OCL-Ly18	M3fzbGNmdGxiVnnhZoltcXS7IFHzd4F6	NFnlTGgxNTVyMDDuUS=>	NVTP[FVUPzJiaB?=	NYnIdIVLTE2VTx?=	Mnnw[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NYizXHJ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNFkzQTVpPkK1NFA6Ojl3PD;hQi=>
OCI-Ly3	MmDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXHn[\|gxOTd{L{K1NE82ODBibl2=	NWfDb2Q{Oi95IHS=	NWrPToVSTE2VTx?=	M1;OWYlv\HWlZYOgZ4VtdC2leXPs[UBienKnc4SgZZQhe3WkLVexJJdqfGhibXnubY1idCClZXzsJIRm[XSqwrC=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTByOUK5OUc,OjVyMEmyPVU9N2F-
OCI-Ly8	NE\LZY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYGxO\|IwOjVyL{WwNEBvVQ>?	MXqyM\|ch\A>?	M3W3RmROW09?	MlXxbY5lfWOnczDj[YxtNWO7Y3zlJIFzemW\|dDDheEB{fWJvR{Gge4l1cCCvaX7pcYFtKGOnbHyg[IVifGkEoB?=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTByOUK5OUc,OjVyMEmyPVU9N2F-
SU-DHL-4	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkDvNVczNzJ3MD:1NFAhdk1?	M2\6dVIwPyCm	NYHlR3cxTE2VTx?=	NHjrdllqdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0JIF1KHO3Yj3HNUB4cXSqIH3pcolu[WxiY3XscEBl\WG2aNMg	NWHV[lZMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNFkzQTVpPkK1NFA6Ojl3PD;hQi=>
SU-DHL-10	NFuwPWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXXDbHpvOTd{L{K1NE82ODBibl2=	Mkj2Nk84KGR?	NYHxd\|NETE2VTx?=	M{TuSIlv\HWlZYOgZ4VtdC2leXPs[UBienKnc4SgZZQhe3WkLVexJJdqfGhibXnubY1idCClZXzsJIRm[XSqwrC=	NGf4cVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCwPVI6PSd-MkWwNFkzQTV:L3G+
OCI-Ly3	MUnBdI9xfG:\|aYOgRZN{[Xl?	NHywVZUyPzJxMkWwJI5O	NGLre3k4\A>?	NXLFSnI6TE2VTx?=	Mn;xbY5kemWjc3XzJINie3Cjc3WtN{84KGGldHn2bZR6yqC\|aXfubYZq[2GwdHz5	MoPrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMEmyPVUoRjJ3MEC5Nlk2RC:jPh?=
OCI-Ly8	MUPBdI9xfG:\|aYOgRZN{[Xl?	NF;rfYIyPzJxMkWwJI5O	MoPFO4Q>	NYPjcoVWTE2VTx?=	NGfZSXZqdmO{ZXHz[ZMh[2G\|cHHz[U0{NzdiYXP0bZZqfHoEoIPp[45q\mmlYX70cJk>	NVLnVVJjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNFkzQTVpPkK1NFA6Ojl3PD;hQi=>
SU-DHL-4	M1nIWGFxd3C2b4Ppd{BCe3OjeR?=	NFnTNGkyPzJxMkWwJI5O	NWnwSXRxP2R?	NVzVXmhlTE2VTx?=	MXrpcoNz\WG\|ZYOgZ4F{eGG\|ZT2zM\|ch[WO2aY\peJnDqHOrZ37p[olk[W62bIm=	MlG2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMEmyPVUoRjJ3MEC5Nlk2RC:jPh?=
SU-DHL-10	MUnBdI9xfG:\|aYOgRZN{[Xl?	NVH1OVlqOTd{L{K1NEBvVQ>?	Mk\SO4Q>	NYT1eZhjTE2VTx?=	M13vdIlv[3KnYYPld{Bk[XOyYYPlMVMwPyCjY4Tpeol1gcLic3nncolncWOjboTsfS=>	NHHsZVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCwPVI6PSd-MkWwNFkzQTV:L3G+
Rosetta2 DE3	MmPnSpVv[3Srb36gZZN{[Xl?				NF3sd5ZM\CB;IECuNFA3OiEQvF2=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB6MEC2OEc,OjZyOECwOlQ9N2F-
Rosetta2 DE3	NVi5UnNFTmy3b4Lld4NmdmOnIIDvcIFzcXqjdHnvckBie3OjeR?=		MYezNEBucW6\|		M1L5O2tqKD1iMD6wNFY3KM7:TR?=	MlnzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOECwOlQoRjJ4MEiwNFY1RC:jPh?=
Rosetta2 DE3	NF\qXZFHfW6ldHnvckBie3OjeR?=				M4nXPGtlKD1iMD6wNFY4KM7:TR?=	Ml64QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOECwOlQoRjJ4MEiwNFY1RC:jPh?=
Rosetta2 DE3	M{jmfWZtfW:{ZYPj[Y5k\SCyb3zhdol7[XSrb36gZZN{[Xl?		NXrVXnB{OzBibXnudy=>		MnnmT4khRSByLkCwO\|Yh\|ryP	NX63WlFZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFAxPjRpPkK2NFgxODZ2PD;hQi=>
Rosetta2 DE3	M4XIb2ZtfW:{ZYPj[Y5k\SCyb3zhdol7[XSrb36gZZN{[Xl?		Ml3ZN\|AhdWmwcx?=		MXrLbUA:KDBwMEC4PUDPxE1?	MkfaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOECwOlQoRjJ4MEiwNFY1RC:jPh?=
Rosetta2 DE3	NVX0dGFtTmy3b4Lld4NmdmOnIIDvcIFzcXqjdHnvckBie3OjeR?=		M2nEflMxKG2rboO=		M3zBRWtqKD1iMD6wNVA4KM7:TR?=	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB6MEC2OEc,OjZyOECwOlQ9N2F-
Rosetta2 DE3	NIWwPZBHfW6ldHnvckBie3OjeR?=				M4foTWtlKD1iMD6wNVE4KM7:TR?=	NGjCTWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC4NFA3PCd-Mk[wPFAxPjR:L3G+
MV4-11	NX7SS2lPSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NHfG[Ic4OiCq		MWTJR\|UxKD1iMD6wNVIh\|ryP	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd\|MUS5NEc,OjZ5M{G0PVA9N2F-
Rosetta2 DE3	Mnu3Sox2d3Knc3PlcoNmKHCxbHHybZpifGmxbjDhd5NigQ>?		NWnNc29oOzBibXnudy=>		NHvQVZpMcSB;IECuNFEzKM7:TR?=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd3OEWxPEc,Ojl5NUi1NVg9N2F-
VCaP	M4KxcGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		M{nBUFEzKGh?		NUnBOXV1UUN3MDC9JFAvODF{IN88US=>	M{m3dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NE[zOFg4Lz5{OES2N\|Q5PzxxYU6=
Rosetta2 DE3	NVi2WlkyTmy3b4Lld4NmdmOnIIDvcIFzcXqjdHnvckBie3OjeR?=		NHu3VoE{OCCvaX7z		MX3LbUA:KDBwMEGyOUDPxE1?	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB6MEC2OEc,OjZyOECwOlQ9N2F-
Rosetta2 DE3	M4G1cGZ2dmO2aX;uJIF{e2G7				NV7WSlRVU2RiPTCwMlAyOjhizszN	NH;Y[GI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC4NFA3PCd-Mk[wPFAxPjR:L3G+
Rosetta2 DE3	MV\GcJVwemW\|Y3XuZ4UheG:uYYLpfoF1cW:wIHHzd4F6		NGflOng{OCCvaX7z		M2HOWGtqKD1iMD6wNVMzKM7:TR?=	MnTMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOECwOlQoRjJ4MEiwNFY1RC:jPh?=
Rosetta2 DE3	NY\SOIE{TnWwY4Tpc44h[XO\|YYm=				NEDBSWhM\CB;IECuNFE{PiEQvF2=	NYK2eItTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFAxPjRpPkK2NFgxODZ2PD;hQi=>
Rosetta2 DE3	NYT1[Hc6TnWwY4Tpc44h[XO\|YYm=				NHzPbI9M\CB;IECuNFE1PyEQvF2=	MoXnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOECwOlQoRjJ4MEiwNFY1RC:jPh?=
Rosetta2 DE3	MljESox2d3Knc3PlcoNmKHCxbHHybZpifGmxbjDhd5NigQ>?		NVrNSXlIOzBibXnudy=>		MUnLbUA:KDBwMEG0PUDPxE1?	M3XXc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NE[zOFg4Lz5{OES2N\|Q5PzxxYU6=
TY82	NGThOI1CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MXy3NkBp		MoDKTWM2OCB;IECuNFE5KM7:TR?=	NIfDXGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEW4OlcyQCd-Mki1PFY4OTh:L3G+
MM1S	NXTNW4pISW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		MmG3O\|IhcA>?		NUPtXoVbUUN3MDC9JFAvODF7IN88US=>	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV6NkexPEc,Ojh3OE[3NVg9N2F-
MM1S	NWX4NJRMS3m2b4TvfIlkcXS7IHHzd4F6		M2\nflczKGh?		MnTyTWM2OCB;IECuNFIh\|ryP	NI\LZoo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe1PFUyQCd-Mkm3OVg2OTh:L3G+
HT-29	Mmi2RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MX6xNkBp		M2XYR2lEPTBiPTCwMlAzKM7:TR?=	NWfkS4hbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1N\|UxPDVpPkK4OVM2ODR3PD;hQi=>
MV4-11	NFnEc\|BIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MlvDO\|IhcA>?		NF7BT5JKSzVyIE2gNE4xOjNizszN	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV3OUSyPEc,OjV3NUm0Nlg9N2F-
MV4-11	MVfDfZRwfG:6aXPpeJkh[XO\|YYm=		NH7XS\|Q1KGSjeYO=		M{GzZ2lEPTBiPTCwMlAzPCEQvF2=	NInXemU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OES2N\|Q5Pyd-Mki0OlM1QDd:L3G+
MV4-11	MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NXL1W\|FzPCCmYYnz		M2C5V2lEPTBiPTCwMlAzPCEQvF2=	M1nFT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEiwNFY1Lz5{NkC4NFA3PDxxYU6=
Rosetta2 DE3	NET0NodHfW6ldHnvckBie3OjeR?=		MUezNEBucW6\|		NXnJeJhSUUN3MDC9JFAvODJ6NzFOwG0>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB6MEC2OEc,OjZyOECwOlQ9N2F-
NALM16	NGLhPGFEgXSxdH;4bYNqfHliYYPzZZk>		MUW1JIRigXN?		MXfFR\|UxKD1iMD6wN{DPxE1?	NH3Bc3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG3NFAzPCd-MkmxO\|AxOjR:L3G+
BL21(DE3)-R3-pRARE2	MVjGeY5kfGmxbjDhd5NigQ>?		M3XTXFMxKG2rboO=		NIDwbmxKSzVyIE2gNE4xOzNizszN	MoPNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhzOUW3NlMoRjJ6MUm1O\|I{RC:jPh?=
BL21(DE3)	M12wSmZ2dmO2aX;uJIF{e2G7				Mo\iT4QhRSByLkCzOEDPxE1?	M1;hclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{OxOFkxLz5{NkezNVQ6ODxxYU6=
Rosetta2 DE3	MXjGcJVwemW\|Y3XuZ4UheG:uYYLpfoF1cW:wIHHzd4F6		NY[3b4F[OzBibXnudy=>		NUDMNY5lUUN3MDC9JFAvODN3NzFOwG0>	NF;FZnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC4NFA3PCd-Mk[wPFAxPjR:L3G+
Rosetta2 DE3	MoKySox2d3Knc3PlcoNmKHCxbHHybZpifGmxbjDhd5NigQ>?		MkfWN\|AhdWmwcx?=		NUnJd\|gxUUN3MDC9JFAvODR{MjFOwG0>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR4M{S4O{c,Ojh2NkO0PFc9N2F-
Rosetta2 DE3	M33vRWZtfW:{ZYPj[Y5k\SCyb3zhdol7[XSrb36gZZN{[Xl?		M3H4ZVMxKG2rboO=		MU\JR\|UxKD1iMD6wOFY4KM7:TR?=	M3vWd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NE[zOFg4Lz5{OES2N\|Q5PzxxYU6=
MOLM13	Ml\qR5l1d3SxeHnjbZR6KGG\|c3H5		Mn7hOEBl[Xm\|		NYHGNZNYUUN3MDC9JFAvODV4IN88US=>	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR4M{S4O{c,Ojh2NkO0PFc9N2F-
MOLM13	MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M3\vVlQh\GG7cx?=		M3uxTmlEPTBiPTCwMlA2PiEQvF2=	Mk\tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOECwOlQoRjJ4MEiwNFY1RC:jPh?=
HL60	MVTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MYG3NkBp		NWPhZ29LUUN3MDC9JFAvODZizszN	M4HEUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUewNFI1Lz5{OUG3NFAzPDxxYU6=
HL60	MnfZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M4fNZ\|Mh\GG7cx?=		MYDHR\|UxKD1iMD6wOkDPxE1?	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTZ3N{C5PUc,Ojl4NUewPVk9N2F-
NALM6	NEi4fVREgXSxdH;4bYNqfHliYYPzZZk>		MVm1JIRigXN?		NWPlS5NbTUN3MDC9JFAvODZizszN	MmDmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3NEm4PFkoRjJ6NUS5PFg6RC:jPh?=
Raji	NGLxXYdHfW6ldHnvckBie3OjeR?=				NX[4b45VUUN3MDC9JFAvODZizszN	M4rOZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{OxOFkxLz5{NkezNVQ6ODxxYU6=
Raji	NEnw[5lHfW6ldHnvckBie3OjeR?=		NGXtWZE1KGh?		NIfEN4lKSzVyIE2gNE4xPjlizszN	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEe1PEc,OjR7MEC3OVg9N2F-
MM1S	MnW5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MYW3NkBp		NUXLeW46UUN3MDC9JFAvODZ7MTFOwG0>	MnHIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3MkW0N\|UoRjJ7NUK1OFM2RC:jPh?=
BL21 (DE3)-codon plus-RIL	MV;GcJVwemW\|Y3XuZ4UheG:uYYLpfoF1cW:wIHHzd4F6		NUXoS5BR[nliZnz1c5Jme2OnbnPlJIFvcXOxdILvdJkh[XO\|YYm=		M2fpcWlEPTBiPTCwMlA4KM7:TR?=	NH3CV4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEW4OlcyQCd-Mki1PFY4OTh:L3G+
22Rv1	M3fvRWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NWHYR5BYQTZiaB?=		NX7BRYd6UUN3MDC9JFAvODdzIN88US=>	NV;Qdo5tRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3OVg2OThpPkK5O\|U5PTF6PD;hQi=>
22Rv1	M1O0dWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NFWwSIcyOiCq		NGflTW9KSzVyIE2gNE4xPzFizszN	NHnpSmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUW0NVM4OSd-Mkm1OFE{PzF:L3G+
MV4-11	M1zONmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7				NUe5UVg2UUN3MDC9JFAvODd{IN88US=>	NYjON2RJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkixPVU4OjNpPkK4NVk2PzJ\|PD;hQi=>
BL21(DE3)-R3-pRARE2	NXm3WYlRTnWwY4Tpc44h[XO\|YYm=		NEG2N2c{OCCvaX7z		MlO5TWM2OCB;IECuNFc4KM7:TR?=	NWDpWVl4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3N\|E1QTBpPkK2O\|MyPDlyPD;hQi=>
BL21(DE3)-R3-pRARE2	NFXvV\|NHfW6ldHnvckBie3OjeR?=		MXmzNEBucW6\|		M1\Fe2lEPTBiPTCwMlA4PyEQvF2=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDF7NUeyN{c,OjhzOUW3NlM9N2F-
BL21(DE3)-R3-pRARE2	NHz3ZW9HfW6ldHnvckBie3OjeR?=		MYSzNEBucW6\|		NUfPWZJtUUN3MDC9JFAvODd5IN88US=>	M1HTZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{e2PFM1Lz5{OUe3Olg{PDxxYU6=
MV4-11	Mn6zR5l1d3SxeHnjbZR6KGG\|c3H5		MV2yOEBp		NV\seHZLT0l3MDC9JFAvODhizszN	M1OyblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUmxN\|Y{Lz5{NkG5NVM3OzxxYU6=
MV411	M4[0bGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MWW3NkBp		NYHHRodrUUN3MDC9JFAvODhizszN	NWPXOVlsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizNVQ2OTNpPkK4N\|E1PTF\|PD;hQi=>
TY82	MnXqRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MnSzO\|IhcA>?		NUTuVlRIUUN3MDC9JFAvODhyODFOwG0>	NIHmbHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWyOVQ{PSd-Mkm1NlU1OzV:L3G+
HL60	NGnwbYtHfW6ldHnvckBie3OjeR?=		MVeyOEBp		NXHoPHRoUUN3MDC9JFAvODh4IN88US=>	M{PjOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NUS5PFg6Lz5{OEW0PVg5QTxxYU6=
697	NFT4WZNEgXSxdH;4bYNqfHliYYPzZZk>		NFXxd4g2KGSjeYO=		M1nCN2VEPTBiPTCwMlA6KM7:TR?=	NF\qTlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG3NFAzPCd-MkmxO\|AxOjR:L3G+
Loucy	NEPCbHZEgXSxdH;4bYNqfHliYYPzZZk>		M3\RXFUh\GG7cx?=		NHLFUnBGSzVyIE2gNE4xQSEQvF2=	Mn;YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzN{CwNlQoRjJ7MUewNFI1RC:jPh?=
BL21(DE3)	NWP2SJl1TnWwY4Tpc44h[XO\|YYm=				MkjVT4QhRSByLkC5NkDPxE1?	M3j6cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUSxN\|cyLz5{OUW0NVM4OTxxYU6=
BL21(DE3)-R3-pRARE2	MmLTSpVv[3Srb36gZZN{[Xl?				NXHX[25VU2RiPTCwMlEh\|ryP	M2[xTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NUm1NFA4Lz5{OEW5OVAxPzxxYU6=
HT-29	M3HaN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NGLuOlE4OiCq		NYjYZoRbUUN3MDC9JFAvOTB2IN88US=>	NELzcZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW1PVQzQCd-MkW1OVk1Ojh:L3G+
MM1S	MoXBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M2fRdVczKGh?		NGDGd2ZKSzVyIE2gNE4yODlizszN	NEHLSVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW1PVQzQCd-MkW1OVk1Ojh:L3G+
LNCAP cells	NWLV[ZRjSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=				NXftNnpNUUN3MDC9JFAvOTB7NjFOwG0>	MnToQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5NUi1NVgoRjJ7N{W4OVE5RC:jPh?=
T cells	M2jqW2Z2dmO2aX;uJIF{e2G7		MnL1NlQhcA>?		M{DNd2lEPTBiPTCwMlEyKM7:TR?=	MnG1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh\|MUS1NVMoRjJ6M{G0OVE{RC:jPh?=
HL60	NInpS5pCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		Mm\WO\|IhcA>?		MWfJR\|UxKD1iMD6xNUDPxE1?	NF:zcVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nki2PVE6PCd-Mk[4OlkyQTR:L3G+
BL21(DE3)	NUPtfmZzTnWwY4Tpc44h[XO\|YYm=				M2\KXWlEPTBiPTCwMlEzKM7:TR?=	NXnFXlhqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3N\|E1QTBpPkK2O\|MyPDlyPD;hQi=>
BL21(DE3)	M4\icGZ2dmO2aX;uJIF{e2G7		Mne2Nk42KGh?		NWixcJVwUUN3MDC9JFAvOTJizszN	NFfpclI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUW0NVM4OSd-Mkm1OFE{PzF:L3G+
H1299	NX;JcW5nTnWwY4Tpc44h[XO\|YYm=		M1TjTVI1KGh?		NVH0OXpzTUN3MDC9JFAvOTV\|IN88US=>	NYDCSXBoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OFk2OjFpPkK4PVQ6PTJzPD;hQi=>
HD-MB03	M2TzfGN6fG:2b4jpZ4l1gSCjc4PhfS=>		NUHSPVdOPSCmYYnz		NXHZeXBRTUN3MDC9JFAvOTZizszN	MkTWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5NUi1NVgoRjJ7N{W4OVE5RC:jPh?=
LNCAP	MVLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NHW4SWg6PiCq		NUnHN4VxUUN3MDC9JFAvOTZizszN	NWrBVGNCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3OVg2OThpPkK5O\|U5PTF6PD;hQi=>
Hs578T	NVTqSmVuSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NH;nNIQyOiCq		M3rxdmlEPTBiPTCwMlE3KM7:TR?=	MmCzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5NUi1NVgoRjJ7N{W4OVE5RC:jPh?=
MV4-11	NWjm[4VXSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		MXSxNkBp		MljQTWM2OCB;IECuNVYh\|ryP	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF5MECyOEc,OjlzN{CwNlQ9N2F-
LNCAP	MorYRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MVWxNkBp		NGeyb4pKSzVyIE2gNE4yPiEQvF2=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV2MUO3NUc,Ojl3NEGzO\|E9N2F-
C4-2B	MomxRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MYO5OkBp		NETnN3FKSzVyIE2gNE4yQSEQvF2=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd3OEWxPEc,Ojl5NUi1NVg9N2F-
C4-2B	NF\CVmdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MX6xNkBp		M3;Rd2lEPTBiPTCwMlE6KM7:TR?=	NXPERY5{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1OFE{PzFpPkK5OVQyOzdzPD;hQi=>
Vero E6	Mn\WRY51cX[rcnHsJIFkfGm4aYT5JIF{e2G7		Mk\pOFghcA>?		MVrJR\|UxKD1iMD6xPVI4PSEQvF2=	MnP6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzJ\|NUO4OVkoRjN{M{WzPFU6RC:jPh?=
MCF7	MUnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MnvWNVIhcA>?		NXXpNmN3UUN3MDC9JFAvOiEQvF2=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd3OEWxPEc,Ojl5NUi1NVg9N2F-
MV4-11	M{ftcmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7				M1vFfWlEPTBiPTCwMlI1KM7:TR?=	NGj5bmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{G0Nlc2OSd-MkexOFI4PTF:L3G+
MV4-11	MmfUR5l1d3SxeHnjbZR6KGG\|c3H5		M3jEPFczKGh?		MYrJR\|UxKD1iMD6yOFIh\|ryP	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzVzN{CxNUc,OjN3MUewNVE9N2F-
MX1	NX\3N3VmSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		MkO1O\|IhcA>?		M{XhdGVEPTBiPTCwMlI2PCEQvF2=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl2OUWyNUc,Ojh7NEm1NlE9N2F-
HT-29	NWr5RYYySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		M2\vVFczKGh?		M3;qO2lEPTBiPTCwMlI5KM7:TR?=	Mk\VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5M{G0PVAoRjJ4N{OxOFkxRC:jPh?=
HFL1	NYnuXJI3SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NXzmdYdnOTJiaB?=		NG\WdXVKSzVyIE2gNE4zQSEQvF2=	NXe3eJpQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3OVg2OThpPkK5O\|U5PTF6PD;hQi=>
MDA-MB-231	NEnpTG5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M3fpbFMh\GG7cx?=		MoXRS2M2OCB;IECuN{DPxE1?	NXrRZm5FRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1OFk5QDlpPkK4OVQ6QDh7PD;hQi=>
MV4-11	NVW2NHZxSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NHyxbYI1QCCq		M3HtR2VEPTBiPTCwMlM{OTF\|IN88US=>	MmHPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3OUWwNFcoRjJ6NUm1NFA4RC:jPh?=
K562	M3jaPWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7				NWXoU2xHUUN3MDC9JFAvPjRizszN	MlfjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzNEK3OVEoRjJ5MUSyO\|UyRC:jPh?=
HL60	MVLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		M1LSW\|Q5KGh?		MVXFR\|UxKD1iMD63OFE{OSEQvF2=	MkDzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3OUWwNFcoRjJ6NUm1NFA4RC:jPh?=
NCI-H1975	MnTYRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MnrNNVIhcA>?		M3\zeWlEPTBiPTCxMlI{KM7:TR?=	M2PjUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{W4OVE5Lz5{OUe1PFUyQDxxYU6=
SAE	Mn[3SpVv[3Srb36gZZN{[Xl?		M{WxTFQhcA>?		MVPJR\|UxKD1iMT6zPEDPxE1?	NYC2WZlzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm2OFk4PDFpPkK5OlQ6PzRzPD;hQi=>
SAE	MWDGeY5kfGmxbjDhd5NigQ>?		MmHmOEBp		MkXITWM2OCB;IEGuOFkh\|ryP	NYDS[3lORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm2OFk4PDFpPkK5OlQ6PzRzPD;hQi=>
SAE	NEXCSXdHfW6ldHnvckBie3OjeR?=		NFL2WVk1KGh?		MofqTWM2OCB;IEGuOVEh\|ryP	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTZ2OUe0NUc,Ojl4NEm3OFE9N2F-
U2OS	NH7rWIxCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MUOxNkBp		MYXJR\|UxKD1iMT62NkDPxE1?	M2jjbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{W4OVE5Lz5{OUe1PFUyQDxxYU6=
SAE	MXPGeY5kfGmxbjDhd5NigQ>?		NWXXXox6PCCq		NYfZXGdDUUN3MDC9JFEvPjNizszN	M1PuS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NkS5O\|QyLz5{OU[0PVc1OTxxYU6=
A549	MWXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		Mn7QNVIhcA>?		NUjRSGt6UUN3MDC9JFEvPjdizszN	M12zblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{W4OVE5Lz5{OUe1PFUyQDxxYU6=
MCF7	MkLRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MVmzJIRigXN?		NGnydHNISzVyIE2gNU44KM7:TR?=	Ml3TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3NEm4PFkoRjJ6NUS5PFg6RC:jPh?=
DU145	MXHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MojtPVYhcA>?		NFXMfXpKSzVyIE2gNk42OiEQvF2=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd3OEWxPEc,Ojl5NUi1NVg9N2F-
DU145	NFToPXJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NYryZWhPOTJiaB?=		MkXGTWM2OCB;IEKuOVIh\|ryP	MkTrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3NEGzO\|EoRjJ7NUSxN\|cyRC:jPh?=
T47D	NIi2O\|NIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MXizJIRigXN?		MXrHR\|UxKD1iMj64JO69VQ>?	NVzjXoFXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1OFk5QDlpPkK4OVQ6QDh7PD;hQi=>
PC3	MWHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NGi5dXo6PiCq		NELyWVVKSzVyIE2gN{4xOSEQvF2=	MlnLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5NUi1NVgoRjJ7N{W4OVE5RC:jPh?=
PC3	NUDGc2p6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NHXFXVMyOiCq		Ml3JTWM2OCB;IEOuNFEh\|ryP	Mmf6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3NEGzO\|EoRjJ7NUSxN\|cyRC:jPh?=
HeLa	MYPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MYixNkBp		MVzJR\|UxKD1iMz63OkDPxE1?	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd3OEWxPEc,Ojl5NUi1NVg9N2F-
K562	NY\rXpBiT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NHrifVc{KGSjeYO=		MlHGS2M2OCB;IEOuPEDPxE1?	M4fuVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NUS5PFg6Lz5{OEW0PVg5QTxxYU6=
A2780	M4PqUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NH7OcZo{KGSjeYO=		NGLRSHZISzVyIE2gOEDPxE1?	M4TFe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NUS5PFg6Lz5{OEW0PVg5QTxxYU6=
HL60	NH3QZpVEgXSxdH;4bYNqfHliYYPzZZk>		NXuydIlROjRiaB?=		MkLCTWM2OCB;IEWuN{DPxE1?	M{T0XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5Mk[2PVk6Lz5{N{K2Olk6QTxxYU6=
MV4-11	NVnWZmw1S3m2b4TvfIlkcXS7IHHzd4F6		MVuyOEBp		NHrsXZdKSzVyIE2gOk41KM7:TR?=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzJ4Nkm5PUc,Ojd{Nk[5PVk9N2F-
K562	M1:5TmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MWS3NkBp		M4\6T2lEPTBiPTC5MlEzKM7:TR?=	NEC4U2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOFUyOyd-MkizNVQ2OTN:L3G+
OVCAR5	M3PoZ2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M132WVMh\GG7cx?=		M3PDfmdEPTBiPTCxNkDPxE1?	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV2OUi4PUc,Ojh3NEm4PFk9N2F-

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pDNA-PKcs / γH2AX / Ub-γH2AX / p-c-Jun S63 / Bax; PubMed: 26119999 Chem Biol The comparative effects of the active (+)-JQ1 vs. the inactive (−)-JQ1 on the cellular responsiveness to radiation and the cell fate decision. c-Myc; PubMed: 23792448 Oncogene PEL and non-PEL (Namalwa) cells treated with indicated doses of (+)-JQ1 for 48 hours were lysed and analyzed by Western blot for the expression of c-Myc. GAPDH was used as a loading control. p27; PubMed: 23792448 Oncogene Western blot analysis showing induction of p27 upon 48 hours of treatment with (+)-JQ1. GAPDH serves as a loading control.	26119999 23792448
Growth inhibition assay	Cell viability; PubMed: 23792448 Oncogene PEL cell lines (BC1, BC3, BCBL1 and JSC1) were treated with indicated doses of (-)-JQ1 or (+)-JQ1 for 5 days and cell viability measured using an MTS assay (refer to Materials and methods). Namalwa, a Burkitt's lymphoma cell line, was used as a control.	23792448
Immunofluorescence	GM130; PubMed: 29074567 Mol Biol Cell Representative images of A549cells treated with single compounds or in combination (as indicated) are shown. MHC / EdU; PubMed: 28733670 Sci Rep C2C12 cultures were switched to DM and treated with 1 µM (+)-JQ1, (−)-JQ1, DMSO or untreated (DM only). Cells were fixed at 12, 24, 48 and 72 hours after treatment and pulsed with EdU 2 hours before fixation. EdU positive nuclei were stained with Alexa Fluor 555 and cultures immunostained for MHC.	29074567 28733670

In vivo

(+)-JQ1 (50 mg/kg) inhibits tumors growth in mice with NMC 797 xenografts. (+)-JQ1 (50 mg/kg) results in effacement of NUT nuclear speckles in mice with NMC 797 xenografts, consistent with competitive binding to nuclear chromatin. (+)-JQ1 (50 mg/kg) induces strong (grade 31) keratin expression in NMC 797 xenografts. (+)-JQ1 (50 mg/kg) promotes differentiation, tumor regression and prolonged survival in mice models of NMC xenografts. ^[1] (+)-JQ1 (50 mg/kg) results in a significant prolongation in overall survival of SCID-beige mice orthotopically xenografted after intravenous injection with MM.1S-luc+ cells compared to vehicle-treated animals. ^[2] (+)-JQ1 (50 mg/kg i.p.) leads to a highly significant increase in survival of mice bearing Raji xenografts. ^[3]

Protocol

Cell Research:

^[1]

- Collapse

Cell lines: MC 11060 cells
Concentrations: ~500 nM
Incubation Time: 48 hours
Method:
Cells are seeded into white, 384-well microtiter plates at 500 cells per well in a total volume of 50 μL media. The 797, TT and TE10 cells are grown in DMEM containing 1% penicillin/streptomycin and 10% FBS. The Per403 cells are grown in DMEM containing 1 % penicillin/streptomycin and 20% FBS. Patient-derived NMC 11060 cells are grown in RPMI with 10% FBS and 1% penicillin/streptomycin. (+)-JQ1 is delivered to microtiter assay plates by robotic pin transfer. Following a 48 hours incubation at 37℃, cells are lysed and wells are assessed for total ATP content using a commercial proliferation assay. Replicate measurements are analyzed with respect to dose and estimates of IC50 are calculated by logistic regression (GraphPad Prism).

(Only for Reference)

Animal Research:

^[1]

- Collapse

Animal Models: Mice bearing NMC 797 xenografts
Dosages: 50 mg/kg
Administration: intraperitoneal injection
(Only for Reference)

References

[4] Li Z, et al. Nucleic Acids Res, 2013, 41(1), 277-287.

- Collapse

Solubility (25°C)

In vitro	DMSO	91 mg/mL warmed (199.12 mM)
	Water	Insoluble
	Ethanol	'91 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download (+)-JQ1 SDF

Molecular Weight	456.99
Formula	C₂₃H₂₅ClN₄O₂S
CAS No.	1268524-70-4
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC1=C(SC2=C1C(=NC(C3=NN=C(N32)C)CC(=O)OC(C)(C)C)C4=CC=C(C=C4)Cl)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How can I reconstitute the compound for in vivo injection?
Answer:
JQ1 does not dissolve in water/PBS. The vehicle we recommend is 2% DMSO+30% PEG 300+5% Tween 80+ddH2O. The compound can be dissolved in the vehicle at 5mg/ml and you can use it for IV injection.

Target Protein Ligand Inhibitors with Unique Features

Pan BET Inhibitor

Bromosporine : Pan-BET inhibitor, BRD2, IC50=0.41 μM; BRD4, IC50=0.29 μM; BRD9, IC50=0.122 μM; CECR2, IC50=0.017 μM.
BET Inhibitor in Clinical Trial

RVX-208 ^New : Phase II for Dyslipidemia.
Newest BET Inhibitor

I-BET-762 : Inhibitor for BET proteins with IC50 of ~35 nM, suppresses the production of proinflammatory proteins by macrophages and blocks acute inflammation, highly selective over other bromodomain-containing proteins.
Classic BET Inhibitor

I-BET151 (GSK1210151A) : Novel selective BET inhibitor for BRD2, BRD3 and BRD4 with IC50 of 0.5 μM, 0.25 μM, and 0.79 μM, respectively.

Choose Your Country or Region

By Signaling Pathways

By product type

(+)-JQ1